Biotech Investment News: Major Pharmaceutical Deals of Boehringer Ingelheim (2015–2025)
Strategic Review: Diversifying into Oncology and Immunology Through Innovative Partnerships Boehringer Ingelheim (BI), traditionally strong in cardiovascular and respiratory areas, has pivoted towards oncology and immune diseases over th...
